Who Paid My Doc
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para
Research payments
$7,187,036
Through program year 2025, $7,187,036 in research payments was reported against A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para, across 1,560 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,128,683 | 524 |
| 2024 | Research | $5,058,353 | 1,036 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jay Brown Marshalltown, IA Named on 89 payments
- Subramaniam Seetharaman Portland, OR Named on 55 payments
- Gary Gross Dallas, TX Named on 51 payments
- Benjamin Bregman Winston Salem, NC Named on 41 payments
- Bernard Grunstra Bristol, TN Named on 38 payments
- Brian Zeno Upper Arlington, OH Named on 35 payments
- Rickey Manning Knoxville, TN Named on 35 payments
- Michael Manning Gilbert, AZ Named on 34 payments
- Randall Ow Roseville, CA Named on 34 payments
- Michael Denenberg Rock Hill, SC Named on 30 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.